BidaskClub lowered shares of EXACT Sciences (NASDAQ:EXAS) from a strong-buy rating to a buy rating in a report issued on Tuesday morning, BidAskClub reports.

A number of other research firms also recently issued reports on EXAS. Canaccord Genuity lifted their price objective on shares of EXACT Sciences from $100.00 to $110.00 and gave the stock a buy rating in a report on Wednesday, May 1st. Craig Hallum reaffirmed a buy rating and set a $115.00 price objective (up from $95.00) on shares of EXACT Sciences in a report on Wednesday, May 1st. Zacks Investment Research raised shares of EXACT Sciences from a sell rating to a hold rating in a report on Tuesday, April 30th. BTIG Research lifted their price objective on shares of EXACT Sciences to $130.00 and gave the stock a buy rating in a report on Wednesday, May 1st. Finally, UBS Group lifted their price objective on shares of EXACT Sciences from $115.00 to $120.00 and gave the stock a buy rating in a report on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. EXACT Sciences currently has an average rating of Buy and a consensus price target of $108.45.

EXAS opened at $110.20 on Tuesday. The firm has a market cap of $14.25 billion, a PE ratio of -81.03 and a beta of 1.68. The company has a quick ratio of 8.13, a current ratio of 8.39 and a debt-to-equity ratio of 1.02. EXACT Sciences has a one year low of $47.78 and a one year high of $111.70.

EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, April 30th. The medical research company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.01). The firm had revenue of $162.00 million for the quarter, compared to analysts’ expectations of $153.07 million. EXACT Sciences had a negative net margin of 41.58% and a negative return on equity of 28.83%. The firm’s revenue for the quarter was up 79.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.33) earnings per share. Sell-side analysts forecast that EXACT Sciences will post -2.21 EPS for the current fiscal year.

In other EXACT Sciences news, insider Mark Stenhouse sold 11,192 shares of the business’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $92.54, for a total value of $1,035,707.68. Following the completion of the sale, the insider now directly owns 25,500 shares of the company’s stock, valued at $2,359,770. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.20% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. GABELLI & Co INVESTMENT ADVISERS INC. lifted its stake in EXACT Sciences by 2.4% in the first quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 4,250 shares of the medical research company’s stock worth $368,000 after purchasing an additional 100 shares during the last quarter. Gofen & Glossberg LLC IL lifted its stake in EXACT Sciences by 1.8% in the first quarter. Gofen & Glossberg LLC IL now owns 8,375 shares of the medical research company’s stock worth $725,000 after purchasing an additional 150 shares during the last quarter. First Hawaiian Bank lifted its stake in EXACT Sciences by 160.0% in the first quarter. First Hawaiian Bank now owns 325 shares of the medical research company’s stock worth $28,000 after purchasing an additional 200 shares during the last quarter. CWM LLC lifted its stake in EXACT Sciences by 35.3% in the first quarter. CWM LLC now owns 831 shares of the medical research company’s stock worth $72,000 after purchasing an additional 217 shares during the last quarter. Finally, Gotham Asset Management LLC lifted its stake in EXACT Sciences by 0.5% in the fourth quarter. Gotham Asset Management LLC now owns 44,047 shares of the medical research company’s stock worth $2,779,000 after purchasing an additional 221 shares during the last quarter. 86.34% of the stock is owned by institutional investors and hedge funds.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Recommended Story: The risks of owning bonds

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.